3 European Projects Found
Searched on 125080 European Projects
FINISHED
Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)
Start date: Nov 1, 2013, End date: Oct 31, 2017,
"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun ...
Read Project
11
Partners Participants
FINISHED
Clinical validation of the CD32b biomarker on the European market (BI-MARK)
Start date: May 1, 2015, End date: Sep 30, 2015,
The overall objective of the proposed project is the clinical validation of a novel biomarker for B-cell malignancies. The presently most widely used anti-CD20 antibody treatment rituximab has considerably improved treatment options for patients with B-cell malignancies. However, effectiveness is limited by resistance to rituximab and reduced response on repeated treatments. Data indicates that tu ...
Read Project
1
Partner Participant
FINISHED
European Consortium for Anticancer Antibody Development (EUCAAD)
Start date: May 1, 2008, End date: Apr 30, 2012,
Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. R ...
Read Project
